Figure 1.
FXII deficiency does not protect against APAP toxicity. (A) Plasma concentration of TAT complexes at 6 and 24 hours post-APAP administration. (B) Plasma ALT activity, an assessment of hepatotoxicity. (C) Histologic scoring of liver pathology according to supplemental Table 1. (D) Representative photomicrographs of liver histology from FXII+/+ and FXII−/− mice at 24 hours after APAP treatment, ×40 and ×100 original magnification. A representative pericentral necrotic lesion is outlined in black. N = 18 to 19 mice per group, combined from 3 independent experiments. Saline samples collected at 24-hour time point (N = 6 mice per group). Error bars represent standard error of the mean.

FXII deficiency does not protect against APAP toxicity. (A) Plasma concentration of TAT complexes at 6 and 24 hours post-APAP administration. (B) Plasma ALT activity, an assessment of hepatotoxicity. (C) Histologic scoring of liver pathology according to supplemental Table 1. (D) Representative photomicrographs of liver histology from FXII+/+ and FXII−/− mice at 24 hours after APAP treatment, ×40 and ×100 original magnification. A representative pericentral necrotic lesion is outlined in black. N = 18 to 19 mice per group, combined from 3 independent experiments. Saline samples collected at 24-hour time point (N = 6 mice per group). Error bars represent standard error of the mean.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal